hTERT inhibition triggers Epstein-Barr virus lytic cycle and apoptosis in immortalized and transformed B cells: A basis for new therapies

Clinical Cancer Research

Volumn 19, Issue 8, 2013, Pages 2036-2047

  Giunco, Silvia ^a   Dolcetti, Riccardo ^c   Keppel, Sonia ^b   Celeghin, Andrea ^a   Indraccolo, Stefano ^b   Dal Col, Jessica ^c   Mastorci, Katy ^c   De Rossi, Anita ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EA D PROTEIN; GANCICLOVIR; GP350 PROTEIN; IMMEDIATE EARLY PROTEIN BZLF1; INITIATION FACTOR 4E BINDING PROTEIN 1; PROTEIN KINASE B; RETROVIRUS VECTOR; SHORT HAIRPIN RNA; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR BATF; TRANSCRIPTION FACTOR FKHRL1; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; B LYMPHOCYTE; BURKITT LYMPHOMA; CELL CYCLE G0 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INHIBITION; EPSTEIN BARR VIRUS; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPHOBLASTOID CELL LINE; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; VIRAL PHENOMENA AND FUNCTIONS; VIRUS LYTIC CYCLE; VIRUS REPLICATION;

ANTIVIRAL AGENTS; APOPTOSIS; B-LYMPHOCYTES; BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; BLOTTING, WESTERN; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELL PROLIFERATION; FLOW CYTOMETRY; GANCICLOVIR; GENE EXPRESSION REGULATION, VIRAL; HERPESVIRUS 4, HUMAN; HOST-PATHOGEN INTERACTIONS; HUMANS; PROTO-ONCOGENE PROTEINS C-AKT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TELOMERASE; TRANS-ACTIVATORS; VIRUS ACTIVATION;

EID: 84877092706     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-2537     Document Type: Article

References (50)

1. Kieff ED, Rickinson AB. Epstein-Barr virus and its replication. In:Knipe DM, Howley PM, editors. Field's virology. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2007. p. 2603-54.
2. Hong GK, Gulley ML, Feng WH, Delecluse HJ, Holley-Guthrie E, Kenney SC. Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model. J Virol 2005;79:13993-4003. (Pubitemid 41552698)
3. Hong GK, Kumar P, Wang L, Damania B, Gulley ML, Delecluse HJ, et al. Epstein-Barr virus lytic infection is required for efficient production of the angiogenesis factor vascular endothelial growth factor in lymphoblastoid cell lines. J Virol 2005;79:13984-92. (Pubitemid 41552697)
4. Ma SD, Hegde S, Young KH, Sullivan R, Rajesh D, Zhou Y, et al. A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas. J Virol 2011;85:165-77.
5. Hanto DW, Frizzera G, Gajl-Peczalska KJ, Sakamoto K, Purtilo DT, Balfour HH Jr, et al. Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation. N Engl J Med 1982;306:913-8. (Pubitemid 12148553)
6. Darenkov IA, Marcarelli MA, Basadonna GP, Friedman AL, Lorber KM, Howe JG, et al. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. Transplantation 1997;64:848-52. (Pubitemid 27422266)
7. Westphal EM, Mauser A, Swenson J, Davis MG, Talarico CL, Kenney SC. Induction of lytic Epstein-Barr virus (EBV) infection in EBV-associated malignancies using adenovirus vectors in vitro and in vivo. Cancer Res 1999;59:1485-91. (Pubitemid 29160115)
8. Feng WH, Israel B, Raab-Traub N, Busson P, Kenney SC. Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors. Cancer Res 2002;62:1920-6. (Pubitemid 34408523)
9. Feng WH, Cohen JI, Fischer S, Li L, Sneller M, Goldbach-Mansky R, et al. Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. J Natl Cancer Inst 2004;96:1691-702. (Pubitemid 39585638)
10. Tang W, Harmon P, Gulley M, Mwansambo C, Kazembe PN, Martinson F, et al. Viral response to chemotehrapy in endemic Burkitt lymphoma. Clin Cancer Res 2010;16:2055-64.
11. Feng WH, Kenney SC. Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression. Cancer Res 2006;66:8762-9. (Pubitemid 44449193)
12. Shirley CM, Chen J, Shamay M, Li H, Zahnow CA, Hayward SD, et al. Bortezomib induction of C/EBPbeta mediates Epstein-Barr virus lytic activation in Burkitt lymphoma. Blood 2011;117:6297-303.
13. Fu DX, Tanhehco Y, Chen J, Foss CA, Fox JJ, Chong JM, et al. Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors. Nat Med 2008;14:1118-22.
14. Moore SM, Cannon JS, Tanhehco YC, Hamzeh FM, Ambinder RF. Induction of Epstein-Barr virus kinases to sensitize tumor cells to nucleoside analogues. Antimicrob Agents Chemother 2001;45:2082-91. (Pubitemid 32591702)
15. Perrine SP, Hermine O, Small T, Suarez F, O'Reilly R, Boulad F, et al. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood 2007;109:2571-8. (Pubitemid 46425904)
16. Kataoka H, Tahara H, Watanabe T, Sugawara M, Ide T, Goto M, et al. Immortalization of immunologically committed Epstein-Barr virus-transformed human B-lymphoblastoid cell lines accompanied by a strong telomerase activity. Differentiation 1997;62:203-11. (Pubitemid 28069811)
17. Sugimoto M, Tahara H, Ide T, Furuichi Y. Steps involved in immortalization and tumorigenesis in human B-lymphoblastoid cell lines transformed by Epstein-Barr virus. Cancer Res 2004;64:3361-4. (Pubitemid 38657904)
18. Jeon JP, Nam HY, Shim SM, Han BG. Sustained viral activity of Epstein-Barr virus contributes to cellular immortalization of lymphoblastoid cell lines. Mol Cells 2009;27:143-8.
19. Terrin L, Dolcetti R, Corradini I, Indraccolo S, Dal Col J, Bertorelle R, et al. hTERT inhibits the Epstein-Barr virus lytic cycle and promotes the proliferation of primary B lymphocytes: implications for EBV-driven lymphomagenesis. Int J Cancer 2007;121:576-87. (Pubitemid 46986491)
20. Harley CB. Telomerase and cancer therapeutics. Nat Rev Cancer 2008;8:167-79. (Pubitemid 351305939)
21. Liu JP, Chen W, Schwarer AP, Li H. Telomerase in cancer immunotherapy. Biochim Biophys Acta 2010;1805:35-42.
22. Ulaner GA, Hu JF, Vu TH, Giudice LC, Hoffman AR. Tissue-specific alternate splicing of human telomerase reverse transcriptase (hTERT) influences telomere lengths during human development. Int J Cancer 2001;91:644-9. (Pubitemid 32115258)
23. Ometto L, Menin C, Masiero S, Bonaldi L, Del Mistro A, Cattelan AM, et al. Molecular profile of Epstein-Barr virus in human immunodeficiency virus type 1-related lymphadenopathies and lymphomas. Blood 1997;90:313-22. (Pubitemid 27276576)
24. Terrin L, Dal Col J, Rampazzo E, Zancai P, Pedrotti M, Ammirabile G, et al. Latent membrane protein 1 of Epstein-Barr virus activates the hTERT promoter and enhances telomerase activity in B lymphocytes. J Virol 2008;82:10175-87.
25. Righetti E, Ballon G, Ometto L, Cattelan AM, Menin C, Zanchetta M, et al. Dynamics of Epstein-Barr virus in HIV-1-infected subjects on highly active antiretroviral therapy. AIDS 2002;16:63-73. (Pubitemid 34062183)
26. Gallagher A, Armstrong AA, MacKenzie J, Shield L, Khan G, Lake A, et al. Detection of Epstein-Barr virus (EBV) genomes in the serum of patients with EBV-associated Hodgkin's disease. Int J Cancer 1999;84:442-8. (Pubitemid 29337135)
27. Trentin L, Ballon G, Ometto L, Perin A, Basso U, Chieco-Bianchi L, et al. Telomerase activity in chronic lymphoproliferative disorders of B-cell lineage. Br J Haematol 1999;106:662-8. (Pubitemid 29434203)
28. Ballon G, Ometto L, Righetti E, Cattelan AM, Masiero S, Zanchetta M, et al. Human immunodeficiency virus type 1 modulates telomerase activity in peripheral blood lymphocytes. J Infect Dis 2001;183:417-24. (Pubitemid 32105601)
29. Colombrino E, Rossi E, Ballon G, Terrin L, Indraccolo S, Chieco-Bianchi L, et al. Human immunodeficiency virus type 1 Tat protein modulates cell cycle and apoptosis in Epstein-Barr virus-immortalized B cells. Exp Cell Res 2004;295:539-48. (Pubitemid 38490505)
30. Dorsey MJ, Tae HJ, Sollenberger KG, Mascarenhas NT, Johansen LM, Taparowsky EJ. B-ATF: a novel human bZIP protein that associates with members of the AP-1 transcription factor family. Oncogene 1995;11:2255-65. (Pubitemid 26008401)
31. Echlin DR, Tae HJ, Mitin N, Taparowsky EJ. B-ATF functions as a negative regulator of AP-1 mediated transcription and blocks cellular transformation by Ras and Fos. Oncogene 2000;19:1752-63. (Pubitemid 30200981)
32. Johansen LM, Deppmann CD, Erickson KD, Coffin WF III, Thornton TM, Humphrey SE, et al. EBNA2 and activated Notch induce expression of BATF. J Virol 2003;77:6029-40. (Pubitemid 36538993)
33. Chen J, Hu CF, Hou JH, Shao Q, Yan LX, Zhu XF, et al. Epstein-Barr virus encoded latent membrane protein 1 regulates mTOR signaling pathway genes which predict poor prognosis of nasopharyngeal carcinoma. J Transl Med 2010;8:30.
34. Armengol G, Rojo F, Castellvi J, Iglesias C, Cuatrecasas M, Pons B, et al. 4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications. Cancer Res 2007;67:7551-5. (Pubitemid 47281345)
35. Kawauchi K, Ogasawara T, Yasuyama M, Otsuka K, Yamada O. The PI3K/Akt pathway as a target in the treatment of hematologic malignancies. Anticancer Agents Med Chem 2009;9:550-9.
36. Gilley J, Coffer PJ, Ham J. FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons. J Cell Biol 2003;162:613-22. (Pubitemid 37022939)
37. Obexer P, Geiger K, Ambros PF, Meister B, Ausserlechner MJ. FKHRL1-mediated expression of Noxa and Bim induces apoptosis via the mitochondria in neuroblastoma cells. Cell Death Differ 2007;14:534-47.
38. Dolcetti R, De Rossi A. Telomere/telomerase interplay in virus-driven and virus-independent lymphomagenesis: pathogenic and clinical implications. Med Res Rev 2012;32:233-53.
39. George J, Banik NL, Ray SK. Knockdown of hTERT and concurrent treatment with interferon-gammainhibited proliferation and invasion of human glioblastoma cell lines. Int J Biochem Cell Biol 2010;42:1164-73.
40. Miri-Moghaddam E, Deezagi A, Soheili ZS, Shariati P. Apoptosis and reduced cell proliferation of HL-60 cell line caused by human telomerase reverse transcriptase inhibition by siRNA. Acta Haematol 2010;124:72-8.
41. Zhong YQ, Xia ZS, Fu YR, Zhu ZH. Knockdown of hTERT by SiRNA suppresses growth of Capan-2 human pancreatic cancer cell via the inhibition of expressions of Bcl-2 and COX-2. J Dig Dis 2010;11:176-84.
42. Kudoh A, Fujita M, Zhang L, Shirata N, Daikoku T, Sugaya Y, et al. Epstein-Barr virus lytic replication elicits ATM checkpoint signal transduction while providing an S-phase-like cellular environment. J Biol Chem 2005;280:8156-63. (Pubitemid 40349716)
43. Gastaldello S, Hildebrand S, Faridani O, Callegari S, Palmkvist M, Di Guglielmo C, et al. A deneddylase encoded by Epstein-Barr virus promotes viral DNA replication by regulating the activity of cullin-RING ligases. Nat Cell Biol 2010;12:351-61.
44. Martelli AM, Evangelisti C, Chappell W, Abrams SL, Bäsecke J, Stivala F, et al. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. Leukemia 2011;25:1064-79.
45. Fukuda M, Longnecker R. Latent membrane protein 2A inhibits transforming growth factor-beta 1-induced apoptosis through the phosphatidylinositol 3-kinase/Akt pathway. J Virol 2004;78:1697-705. (Pubitemid 38176702)
46. Shair KH, Bendt KM, Edwards RH, Bedford EC, Nielsen JN, Raab-Traub N. EBV latent membrane protein 1 activates Akt, NFkappaB, and Stat3 in B cell lymphomas. PLoS Pathog 2007;3:e166.
47. Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 2006;107:257-64. (Pubitemid 43053550)
48. Roue G, Lopez-Guerra M, Milpied P, Pérez-Galán P, Villamor N, Montserrat E, et al. Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling. Clin Cancer Res 2008;14:6907-15.
49. Yee J, White RE, Anderton E, Allday MJ. Latent Epstein-Barr virus can inhibit apoptosis in B cells by blocking the induction of NOXA expression. PLoS ONE 2011;6:e28506.
50. Roth A, Harley CB, Baerlocher GM. Imetelstat (GRN163L)-telomerase-based cancer therapy. Recent Results Cancer Res 2010;184:221-34.